艾迪注射液联合靶向药物治疗非小细胞肺癌的临床疗效

Short-Term Clinical Efficacy of Aidi Injection Combined with Targeted Drugs in the Treatment of Non-small Cell Lung Cancer

目的探究艾迪注射液联合靶向药物治疗非小细胞肺癌的临床疗效。方法回顾性分析2012年3月至2015年3月于保定市第三中心医院就诊的152例非小细胞肺癌患者的临床资料,依据治疗方法不同分为对照组和观察组,各76例。对照组口服地塞米松及空腹口服吉非替尼250 mg/d进行治疗;观察组在对照组治疗基础上联合艾迪注射液50 m L溶于500 m L 0.9%Na Cl注射液静脉注射,每日1次,3周为1个疗程。观察比较两组患者的临床疗效,治疗前后表皮生长因子受体(EGFR)、癌胚抗原(CEA)、白细胞计数(WBC)、血小板计数(PLT)、丙氨酸转氨酶(ALT)、卡氏评分(KPS)及治疗过程中不良反应发生情况。结果观察组临床治疗总有效率显著高于对照组[53.95%(41/76)比34.21%(26/76)](P<0.05)。治疗后,观察组患者EGFR、CEA及ALT显著低于对照组[(13.5±2.2)ng/L比(17.5±2.7)ng/L,(67±13)mg/L比(84±20)mg/L,(50±11)U/L比(63±14)U/L](P<0.01),观察组患者的WBC及PLT显著高于对照组[(4.2±0.6)×10~9/L比(3.4±0.4)×10~9/L,(96.4±24.0)×10~9/L比(81.0±23.5)×10~9/L](P<0.01);治疗后,观察组患者的KPS显著高于对照组[(79.3±7.1)分比(73.6±6.8)分](P<0.01)。治疗过程中观察组患者腹泻、呕吐及脱发发生率低于对照组(P<0.01)。结论艾迪注射液联合靶向药物对非小细胞肺癌患者具有明显疗效且不良反应轻微。

Objective To explore the effect of treatment of targeted therapy and Aidi injection on the patients with non-small cell lung cancer. Methods A total of 152 patients with non-small cell lung cancer who were treated at the Third Central Hospital of Baoding from Mar. 2012 to Mar. 2015 were retrospectively analyzed. 76 patients in the control group were treated with oral administration of dexamethasone and gefitinib of 250 mg/d ;76 patients in the observation group were treated with 50 mL of Aidi injection in diluted in 500 mL of saline on the basis of the control group＇s regimen,once a day, 3 weeks as a course of treatment. The clinical effect of the two groups was compared, epidermal growth factor receptor （ EGFR）, careinoembryonic antigen （ CEA ）, white blood cell （ WBC ）, platelet （ PLT ）, aminotransferase （ ALT ）, Karnofsky score（KPS） ,the clinical efficacy and the adverse reactions were detected before and during the treatment. Results The clinical treatment efficiency of the observation group was significantly higher than that of the control group[53.95% （41/ 76） vs 34.21% （26/76） ] （ P 〈 0.05 ）. After treatment, the EGFR, CEA and ALT of the observation group were lower than those of the control group [ （ 13.5 ± 2.2） ng/L vs （ 17.5 ± 2.7 ） ng/L, （67 ± 13 ） mg/L vs （ 84 ± 20 ） mg/L, （ 50 ± 11 ） U/L vs （63 ± 14） U/L] （P 〈 0. 01 ）, WBC, PLT and KPS were significandy higher than those of the control group （4.2± 0.6） × 109/L vs （3.4 ± 0.4） ×109/L, （96.4 ±24.0） x 109/L vs （81. 0± 23.5） × 109/L, （79.3±7.1 ） scores vs （ 73.6±6.8 ） scores ] （ P 〈 0. 01 ）. During the treatment, ratios of diarrhea, vomiting and hair loss of the observation group were lower than those of the control group （P 〈 0.01 ）. Conclusion Aidi injection combined with targeted drug has a significant effect and mild adverse reactions for patients with non-small cell lung cancer.